{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=2", "query": { "intervention": "Brentuximab vedotin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 123, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T02:00:50.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02729961", "title": "Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Positive", "CD30-Positive Neoplastic Cells Present", "Systemic Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2018-01-03", "completion_date": "2023-07-01", "has_results": false, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02729961" }, { "nct_id": "NCT01309789", "title": "A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, NK-cell", "Lymphoma, T-cell" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2011-02", "completion_date": "2017-02-28", "has_results": false, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309789" }, { "nct_id": "NCT00365274", "title": "SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "SGN-30", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2006-08", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365274" }, { "nct_id": "NCT01476410", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage IV Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "DNA analysis", "type": "GENETIC" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC", "RADIATION", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 49, "start_date": "2011-11", "completion_date": "2020-05-26", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 7, "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476410" }, { "nct_id": "NCT01700751", "title": "Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Acute Myeloid", "Leukemia, Lymphoblastic,Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 17, "start_date": "2013-02-25", "completion_date": "2016-11-21", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01700751" }, { "nct_id": "NCT03719105", "title": "Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "NK-Cell Lymphoma", "NK-Cell Leukemia", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "pralatraxate,", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "calaspargase pegol", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "31 Years", "sex": "ALL", "summary": "1 Year to 31 Years" }, "enrollment_count": 40, "start_date": "2019-03-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719105" }, { "nct_id": "NCT03587844", "title": "Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycosis Fungoides", "Lymphomatoid Papulosis", "Sezary Syndrome" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2018-07-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 8, "location_summary": "Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587844" }, { "nct_id": "NCT01100502", "title": "A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Disease, Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2010-04-30", "completion_date": "2020-04-27", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 32, "location_summary": "Duarte, California • San Francisco, California • Stanford, California + 26 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100502" }, { "nct_id": "NCT04685616", "title": "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Involved site radiotherapy", "type": "RADIATION" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Haematopoietic growth factor", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University College, London", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 1042, "start_date": "2022-04-14", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 3, "location_summary": "Stanford, California • Miami, Florida • New York, New York", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04685616" }, { "nct_id": "NCT04138875", "title": "A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTLD", "Lymphoid Tumor", "Hematopoietic/Lymphoid Cancer", "Plasmacytic Hyperplasia PTLD", "Infectious Mononucleosis", "Florid Follicular Hyperplasia PTLD", "Polymorphic PTLD", "Monomorphic PTLD", "Classical Hodgkin Lymphoma Type PTLD" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2022-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-06-23", "last_synced_at": "2026-10-06T02:00:50.910Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Rochester, Minnesota", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138875" } ] }